NP-101

DRUG2 trials

Sponsors

Novatek Pharmaceuticals, M.D. Anderson Cancer Center

Conditions

COVID-19Solid Tumor

Phase 1

Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors

RecruitingNCT06563375

M.D. Anderson Cancer CenterSolid Tumor

Start: 2025-03-05End: 2030-09-01Target: 35Updated: 2026-03-12

Phase 2

Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.

TerminatedNCT05785390

Novatek PharmaceuticalsCOVID-19

Start: 2023-02-22End: 2025-05-09Updated: 2026-08-13